Serotonergic influence on cholinergic-induced analgesia: differences in two inbred strains of mice

C57BL/6 (C57) and DBA/2 (DBA) inbred mice showed different analgesic responses to cholinergic stimulation. The simultaneous administration of muscarinic and serotonergic agonists, oxotremorine and 5-methoxy-NN-dimethyltryptamine (5-MeODMT), lowered the antinociceptive effect of the cholinergic drug in DBA mice, while no effects were detectable in the C57 strain. These results suggest a strain-dependent behavioural effect of the interaction of cholinergic and serotonergic neuronal systems.     

Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligands

A set of novel heterocyclic ligands (7a-9a, 7b-9b, and 9c) structurally related to oxotremorine 2 was designed, synthesized, and tested at muscarinic receptor subtypes. In the binding experiments at cloned hm1-5, the presence of the 2-methylimidazole/2-methyl-3-alkylimidazolium moiety in place of the pyrrolidine ring revealed, in derivatives 8a, 8b, and 9c, a moderate selectivity for some receptor subtypes. The functional in vitro assays yielded results that correlated closely to binding data. In general, on passing from agonists bearing the pyrrolidine moiety to their analogues carrying the 2-methylimidazole function, the overall pharmacological efficacy profile is shifted from agonism toward partial agonism. The insertion of the 2-methyl-3-alkylimidazolium moiety advances the effect such that the compounds are pure antagonists. Quite similarly, chiral 3-oxo-Delta(2)-isoxazoline (+/-)-10 behaved as a weak antagonist unable to discriminate the different muscarinic receptor subtypes.     

Enhancement of tyrosine hydroxylase activity by Oxotremorine does not affect sleep in the rat

Marked enhancement of tyrosine hydroxylase (TH) activity was observed in the rostral pons of Wistar albino rats, 3 days after a single injection of Oxotremorine. TH activity in other brain areas, and regional levels of norepinephrine, dopamine, serotonin and 5-hydroxyindoleacetic acid were unaffected. Enhancement of TH activity did not affect length or number of REM episodes, or the amount of REM occurring in 24 hr. REM occurrence did not, thus, vary in accordance with activity of the rate-limiting enzyme for catecholamine synthesis. These data suggest that, although REM may reflect neuronal protein synthesis, REM is not part of a mechanism regulating the activity of enzymes in the pontine CA synthesis pathway.     

Discriminative stimulus properties of muscarinic agonists

In a two-lever, food-reinforced drug-discrimination paradigm separate groups of rats were trained to discriminate either arecoline, pilocarpine or oxotremorine from saline. The discriminative cues of all three agonists were potently blocked by scopolamine, but only by 30–60 fold higher doses of methylscopolamine. The three agonists all suppressed overall response rate. These rate-suppressant effects were not blocked by scopolamine in doses which blocked the discriminative cues. In generalization tests, arecoline elicited selection of the drug-appropriate lever in all groups of trained animals. Pilocarpine was discriminated as drug by all pilocarpine-trained animals and by a majority of oxotremorine-trained animals, but was not significantly discriminated by the arecoline-trained group. Oxotremorine was discriminated by all oxotremorine-trained animals but only by some pilocarpine-trained animals, and was not significantly discriminated by the arecoline-trained group. Morphine, haloperidol, chlordiazepoxide, pentobarbital and nicotine were not generalized to any of the training drugs. The discriminative stimuli produced by the training drugs are therefore specific and exhibit properties indicative of an origin at central muscarinic receptors but may not be identical.     

Effects of oxotremorine on inhibitory avoidance behaviour in two inbred strains of mice: interaction with 5-methoxy-NN-dimethyltriptamine

The effects of the cholinergic muscarinic agonist, oxotremorine (0.005, 0.01, 0.02 and 0.04 mg/kg), the serotonergic agonist, 5-methoxy-NN-dimethyltriptamine (5-MeODMT) (0.5, 1 and 2 mg/kg), and their combination, were investigated in C57BL/6 and DBA/2 mice using a one-trial inhibitory avoidance task, drug treatment being given immediately after the acquisition trial. Post-trial administration of oxotremorine facilitated, while post-trial administration of 5-MeODMT inhibited memory retention of both strains in a dose-dependent fashion. The DBA/2 strain was more affected by oxotremorine than the C57BL/6 mice; no strain-dependent sensitivity to serotonergic agonist administration was observed. In both strains, the combination of oxotremorine plus 5-MeODMT inhibited the performance improvement shown by the administration of the cholinergic agonist alone. The facilitatory role of cholinergic stimulation on retention performance was confirmed and an inhibitory action of the serotonergic system on memory processes was suggested. Moreover, the present results support a functional interaction between cholinergic and serotonergic systems on memory consolidation.     

Memory retention: potentiation of cholinergic drug combinations in mice

The amnesias characteristic of Alzheimer's disease and other age-related dementias are refractory to conventional pharmacotherapy. A recent strategy is to combined present drugs, to improve their memory enhancing effect. We utilize mice weakly trained on active avoidance in a T-maze in order to compare the effect on retention test performance of cholinergic drugs given alone and in two-drug and three-drug combinations. All drugs were injected intraventricularly immediately after training. Memory retention was tested one week later. A dose-response curve was determined for each of four drugs (arecoline, edrophonium, oxotremorine, deanol) and for several of their fixed-ratio combinations. The results indicate that each drug and each combination improved retention test performance up to an optimal dose; the improvement decreased with further increases in dose. A striking reduction (as much as 95%) in the optimal dose for enhanced retention was observed with these two-drug combinations, and further reduction with a three-drug combination. The practical implications of planned drug interactions as an improved means of treating amnesias associated with aging are under investigation.     

Modulation of stimulation-evoked release of newly formed acetylcholine from mouse hemidiaphragm preparation

Summary A radioisotope method has been developed for measuring the stimulation-evoked release of acetylcholine without the use of cholinesterase inhibitors from the mouse hemidiaphragm preparation which had been loaded with ³H-choline. Evidence has been obtained that ³H-choline was taken up by and released from both innervated and non-innervated mouse hemidiaphragm preparations. However, it was released in the form of ³H-acetylcholine in response to electrical field stimulation only from the innervated preparations. Long lasting (51 min) S₁ stimulation of the preparations exhausted the radioactive acetylcholine stores to the extent that S₂ did not evoke any release of ³H. These data suggest that when the labelled acetylcholine stores become exhausted, the labelled choline, still present in the tissue, cannot be released by electrical stimulation. Tetrodotoxin (1 mol/1) administration and Ca withdrawal inhibited, 20–100 mol/l 4-aminopyridine enhanced the release of ³H-acetylcholine in response to electrical stimulation. Activation of the presynaptic muscarinic receptors by the agonist oxotremorine (50 mol/l) decreased the liberation of ³H-acetylcholine. The muscarinic antagonist atropine (1 mol/l) abolished the inhibitory effect of oxotremorine and by itself increased the evoked release of the newly formed ³H-acetylcholine. Adenosine (50 gmol/l) reduced the evoked release of radioactivity. Theophylline (30 mol/l) prevented the inhibitory effect of adenosine and itself enhanced the release. Xylazine (1 mol/l), an alpha₂-adrenoceptor agonist did not affect the release. It is concluded that the stimulation-evoked release of ³H-acetylcholine from the mouse phrenic nerve hemidiaphragm preparation preloaded with ³H-choline is derived from the motor nerves. The release of acetylcholine is modulated by activation of presynaptic muscarinic and adenosine receptors. Send offprint requests to G. T. Somogyi at the above address     

Release of endogenous acetylcholine in the hypothalamus of conscious rats

Summary The release of endogenous acetylcholine was investigated by the push-pull technique. The posterior hypothalamus of conscious rats was superfused through a push-pull cannula with artificial cerebrospinal fluid (ACSF) which contained 1 mol/l neostigmine. Acetylcholine was determined in the superfusate by high pressure liquid chromatography and electrochemical detection. Hypothalamic superfusion with potassium-rich (100 mmol/l) ACSF led to a pronounced increase in the release rate of acetylcholine. Tetrodotoxin (1 mol/l) almost abolished the basal release of the neurotransmitter. Superfusion of the hypothalamus with atropine (10 or 50 mol/l) led to a concentration-dependent increase, whereas superfusion with oxotremorine (50 mol/l) inhibited the release rate of acetylcholine. It is concluded that acetylcholine released into the superfusate of the hypothalamus originates from cholinergic neurons. Furthermore, the release of acetylcholine seems to be modulated by muscarinic acetylcholine receptors, probably located on cholinergic neurons of the hypothalamus.This work was supported by the Fonds zur Förderung der wissenschaftlichen Forschung Send offprint requests to H. Prast at the above address     

精氨酸加压素V1受体阻断剂对氧化震颤素引起低温反应的影响

目的 本研究旨在探讨内源性精氨酸加压素(AVP)是否参与M胆碱激动剂氧化震颤素(OXO)引起的低温反应.方法 用无线遥测技术测量大鼠的体温和活动变化,观察腹腔注射AVP V1受体阻断剂对OXO引起的体温和活动变化的影响.结果 给大鼠皮下注射OXO能引起明显的低温反应,大约4h后恢复到对照水平.腹腔注射AVP V1阻断剂可以明显阻断OXO的低温效应.结论 AVP V1受体阻断剂可以阻断OXO引起的低温作用,提示OXO引起的降温效应可能是通过AVP的释放所致.     

Applicability of the isolated perfused rat brain for studying central cholinergic mechanisms

Summary The ACh content of the isolated perfused rat brain as well as that of the rat brain in vivo was determined by gas chromatography. After a perfusion period of 30 min the endogenous ACh content of the isolated brain was significantly higher than that of the brain in vivo. Physostigmine caused a rise in the ACh concentration of both the isolated brain and the brain in vivo. Oxotremorine produced an increase in the ACh content in the brain in vivo, but not in the isolated brain after appropriate dosage.The concentration of the drugs in the perfusion medium of the isolated brain was so that distinct EEG changes could be observed but spontaneous electrical activity could be maintained during the whole perfusion period.